[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"suicide\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:suicide":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,80,0,25,[9,43,71,106,152,178,212,241,264,290,310,330,357,390,420,447,473,499,520,540,559,587,611,634,659],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100508188","trial-of-device-that-is-not-approved-or-cleared-by-the-us-fda-100508188",false,"NCT05897164","Mobile Technology to Reduce Teen Substance Misuse","iKinnect Mobile Technology to Reduce Teen Substance Misuse and Health Disparities","INCLUSION CRITERIA:\n\nYouth:\n\n* Resides in United States\n* 13-17 years of age\n* Fluent in English\n* Possesses and is the primary user of an Android or iPhone-based smartphone with a data plan that they use on a daily basis\n* Currently residing in the same household with the linked caregiver\u002Flegal guardian participant at least five days a week\n* Meets criteria for mild-moderate or severe SA (for any drug or alcohol) on the Screening to Brief Intervention (S2BI), indicated by answering that they have used any substance at least once per month within the past 90 days.\n* Possesses and is the primary user of an Android or iPhone-based smartphone with a data plan\n\nCaregivers:\n\n* Resides in United States\n* 18 years or older\n* Fluent in English\n* Owns and is the primary user of an Android or iPhone-based smartphone with a data plan that they use on a daily basis\n* Able and willing to receive and send several (1-3 times\u002Fweek) text messages from study staff during study participation\n* Is the primary caregiver of a youth aged 13-17 years who lives in the caregiver's home at least five days a week\n* Caregiver indicates a substance concern for the target youth, defined as either a+b OR c:\n\n  1. uses alcohol, marijuana, and\u002For another substance, AND\n  2. expresses that they are concerned (a score of 3 or higher) about that use on a 5-pt Likert scale (3 = concerned, 4 = very concerned, 5 = extremely concerned).\n\n     OR\n  3. The target youth participated in counseling or another form of treatment (e.g., medication assisted treatment) because of a concern about alcohol, marijuana, or other substance use.\n\n     EXCLUSION CRITERIA\n\n     Youth:\n* Participated in previous iKinnect or WisePath for Teens research in the past 2 years\n\nCaregivers:\n\n* Participated in previous iKinnect or WisePath for Teens research in the past 2 years\n* Currently involved with the child protective service system due to a concern about child maltreatment (i.e., abuse or neglect).","ALL","13 Years",{"count":20,"type":21},600,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this study is to test the newly expanded WisePath for Teens (WPT) for substance use app, a direct-to-consumer paired mobile phone app for iOS and Android platforms that supports parents\u002Fguardians in delivering evidence-based techniques to reduce youth substance abuse and co-occurring mental health problems. This project will expand WPT for use with a general population of teens with problematic substance use and their parents to reduce substance abuse, its harmful effects, opioid overdoses, and progression to substance use disorders, as well as other behavioral health problems that are exacerbated by substance abuse and\u002For interfere with substance abuse treatment.",[27,28,29,30],"Substance Use","Substance Abuse","Suicide","Adolescent","RECRUITING","2026-08-18",{"date":34,"type":35},"2026-08-20","ACTUAL",{"date":32,"type":35},{"date":38,"type":21},"2027-04-30",{"name":40,"class":41},"Evidence-Based Practice Institute, Seattle, WA","INDUSTRY",2,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100502712","pilot-study-of-health-systemcommunity-partnership-for-enhanced-outreach-to-prevent-suicide-attempts-100502712","NCT05825820","Pilot Study of Health System\u002FCommunity Partnership for Enhanced Outreach to Prevent Suicide Attempts","Pilot Study Health System\u002FCommunity Partnership for Enhanced Outreach to Prevent Suicide Attempts","Inclusion Criteria:\n\n1. Currently a patient being treated and evaluated by psychiatry service in an MGB ED\n2. Participants enrolled in another study (NCT05671133; PI Nock) conducted by the research team who fall into the top 50% of risk based on the suicide risk prediction algorithm used in that study\n3. Able to read English\n4. Ownership of a smartphone (iOS or Android) and consistent access to their smartphone following discharge from the current treatment unit or program; ability to be reliably contacted\n5. Willing to provide contact information for collateral contact\n6. Willing to share contact information and key clinical information with Samaritans of Boston\n7. Consent to unencrypted text or email communications\n8. Willing to provide social security number (SSN) or individual taxpayer identification number (ITIN) for study compensation\n\nExclusion Criteria:\n\n1. Any factor that impairs an individual's ability to comprehend and effectively participate in informed consent, including the presence of gross cognitive impairment due to florid psychosis, intellectual disability, dementia, or acute intoxication\n2. Presence of extremely agitated or violent behavior at the time of consent or enrollment","18 Years",{"count":52,"type":21},20,[24],"The goal of this clinical trial is to test an enhanced outreach intervention (EOI) delivered by Samaritans of Boston (a community organization that provides support during mental health crises) for people after they leave an emergency department (ED) visit for suicidal thoughts. The main questions the trial aims to answer are:\n\n* Is the EOI feasible and acceptable?\n* Can the EOI be delivered with fidelity by Samaritans staff?\n\nParticipants will:\n\n* Receive outreach (by call or text) once per week for 12 weeks after ED visit. During these conversations, Samaritans staff will ask participants questions about their suicidal thoughts and behaviors, develop and review a list of coping skills to use if they have suicidal thoughts, and discuss plans for receiving mental health care.\n* Receive caring messages from Samaritans staff at least once per week.\n* Be asked to complete monthly self-report questionnaires, and participate in a phone interview with study staff at the end of the study.",[29,56,57],"Suicide, Attempted","Suicidal Ideation",[29,59],"Suicidal Thoughts","2026-08-14",{"date":62,"type":35},"2026-08-17",{"date":64,"type":35},"2026-07-31",{"date":66,"type":21},"2027-02",{"name":68,"class":69},"Massachusetts General Hospital","OTHER",1,{"id":72,"slug":73,"hasResults":12,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":17,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100471990","mental-health-in-primary-care-100471990","NCT05426057","Mental Health in Primary Care","Scaling a Parenting Evidence Based Intervention (EBI) for Latinx Youth Mental Health in Primary Care","Inclusion Criteria:\n\n1. Female and male adolescents, who self-identify as Hispanic (or Latino(a))\n2. Adolescent between the ages of 12 - 16 years\n3. Adolescent living with an adult primary caregiver who is willing to participate\n4. Families must have broadband internet access on a device, including (but not limited to) a smartphone, iPad, tablet, computer at their home or other location (e.g., school, library, etc.)\n5. Families screening positive on poor family communication (a score of less than 75 on the communication measure; see measures) or youth reporting elevated depressive or anxiety symptom scores (defined as 70 to 90 on the K-CAT) or a history of suicide behavior (ideation or attempts).\n\nExclusion Criteria:\n\n* Families reporting plans to move out of the South Florida area during the study period.",true,"12 Years","16 Years",{"count":82,"type":21},468,[24],"The goal of this study is to evaluate in an effectiveness-implementation type I hybrid trial, an enhanced version of eHealth Familias Unidas for reducing depressive, anxious symptoms and suicide behavior in Hispanic youth. The study will use a randomized rollout design with 18 pediatric primary care clinics in the South Florida area.",[86,29,87],"Depression, Anxiety","Drug Use",[89,90,91,92,93,94,95,96,97],"effectiveness-implementation type 1 hybrid trial","Latinx mental health in primary care","Latinx adolescent","eHealth intervention","Familias Unidas","intervention sustainment","parent-centered","family functioning","sexual risk behavior",{"date":32,"type":35},{"date":100,"type":35},"2022-04-26",{"date":102,"type":21},"2028-04-30",{"name":104,"class":69},"University of Miami",17,{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":116,"conditions":117,"keywords":138,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":70},"100551600","natural-history-of-depression-bipolar-disorder-and-suicide-risk-100551600","NCT06462196","Natural History of Depression, Bipolar Disorder and Suicide Risk","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Signed consent for Protocol 01-M-0254: The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Volunteers\n* Age 18 years or older\n* Able to provide informed consent\n* Able to read and write English\n\nEXCLUSION CRITERIA:\n\n* Unstable medical conditions in the opinion of the investigator that would preclude participation in outpatient or inpatient treatment.\n* Pregnancy\n* Participation in the Protocol 01-M-0254: The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Volunteers, as a healthy volunteer.\n* Participants with a history of DSM-IV substance or alcohol abuse or dependence, or DSM-5 substance use disorder (except for caffeine, nicotine, or cannabis), or moderate to severe alcohol use disorder, within the preceding three months. In addition, participants who are currently using drugs (except for caffeine, nicotine, or cannabis) must not have used illicit substances or known drugs of abuse in the two weeks prior to consent and must have a negative drug urine test (except for prescribed benzodiazepines or stimulants) prior to enrolling in the study. Cannabis use is exclusionary if the use is daily, or if participants are unable to abstain during the study, or if function of daily life is impaired by use as determined by a clinician.","120 Years",{"count":114,"type":21},500,"OBSERVATIONAL","Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments. In this study, researchers want to perform tests on people undergoing clinical care for mood disorders. The purpose is to understand the experience of receiving treatment for depression, bipolar disorder, and suicide risk. We also hope that this study will help us to predict which medications will improve thoughts of suicide.\n\nPeople 18 years or older who are receiving treatment for depression, bipolar disorder, or suicide risk may take part in this study. Participants must have also been enrolled in protocol 01-M-0254.\n\nThis study will be conducted at the NIH Clinical Center in Bethesda, MD. The study typically lasts up to 12 weeks, but may last longer if a participant s treatment continues past that time.\n\nParticipants will have weekly interviews and questionnaires while they are being treated for their mood disorder. Other tests are optional and include psychological testing, blood draws, sleep tests, and imaging scans. These will be done at the start and the end of research participation.",[118,29,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137],"Behavioral Symptoms","Self-Injurious Behavior","Sensory System Agents","Analgesics","Peripheral Nervous System Agents","Physiological Effects of Drugs","Anesthetics, Dissociative","Anesthetics, General","Anesthetics","Central Nervous System Depressants","Excitatory Amino Acid Antagonists","Excitatory Amino Acid Agents","Neurotransmitter Agents","Molecular Mechanisms of Pharmacological Action","Ketamine","Depression, Unipolar","Depressive Symptoms","Treatment Resistant Depression","Major Depressive Disorder","Depression, Bipolar",[139,29,136,140,141,142,135],"Neurobiology","Bipolar Disorder","Biomarkers","Suicide Risk","2026-08-13",{"date":60,"type":35},{"date":146,"type":35},"2024-09-09",{"date":148,"type":21},"2030-06-01",{"name":150,"class":151},"National Institute of Mental Health (NIMH)","NIH",{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":171,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":70},"100486430","integrated-suicide--trauma-therapy-for-suicide-risk-100486430","NCT05613972","Integrated Suicide & Trauma Therapy for Suicide Risk","Using Integrated Suicide and Trauma Therapy to Reduce Suicide Risk Among Adults With a History of Childhood Trauma","ISTT","Inclusion Criteria:\n\n* Beck Scale for Suicidal Ideation \\> 10\n* Presence of childhood trauma defined by a minimum moderate score on any of the Childhood Trauma Questionnaire subscales (emotional abuse, physical, abuse, sexual abuse, emotional neglect, and physical neglect\n* any psychiatric diagnosis as long as there are no impairments that limit consent or understanding of ISTT (e.g. active psychosis)\n* Ability to provide informed consent\n* Not receiving other psychotherapy concurrently\n* Ability to undergo psychotherapy in English\n\nExclusion Criteria:\n\n* The presence of cognitive impairment and\u002For active psychosis that would limit consent or understanding of ISTT\n* Unwilling or unable to provide informed consent",{"count":52,"type":21},[24],"The investigators have developed a novel suicide intervention, Integrated Suicide and Trauma Therapy (ISTT). ISTT combines Brief-Skills for Safer Living (Brief-SfSL)-a promising method to enhance coping skills and reduce suicidality-with a trauma therapy component to alleviate the specific impacts of childhood trauma on suicide risk. The aim of this pilot is to test 12-weeks of ISTT to alleviate suicide risk among individuals with a history of childhood trauma and current suicidality.",[29,164,136],"Trauma",[166,167,168,169,170],"Childhood trauma","Early life adversity","Adverse childhood experiences","Suicide intervention","Psychotherapy",{"date":62,"type":35},{"date":173,"type":35},"2025-12-08",{"date":175,"type":21},"2027-07",{"name":177,"class":69},"Unity Health Toronto",{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":190,"conditions":191,"keywords":194,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":211},"100619749","a-just-in-time-adaptive-intervention-for-suicide-safety-planning-in-adolescents-100619749","NCT07348666","A Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents","BRITE 2.0: A Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents (ViraSafe RCT (SBIR Phase 2))","ViraSafeRCT","Inclusion Criteria:\n\nYouth (minors):\n\n* 13-17 years old\n* Suicide attempt in the last year and ideation in the past month\n* English fluency and literacy\n* Parent or legal guardian willing and able to legally provide informed consent\n* Receiving care at one of the study clinical settings with trained providers to onboard ViraSafe or BRITE safety plan\n\nYouth (adults)\n\n* 18-24 years old\n* Recent suicide attempt or ideation with a plan\n* English fluency and literacy\n* Receiving care at one of the study clinical settings with trained providers to onboard ViraSafe or BRITE safety plan.\n\nExclusion Criteria:\n\nYouth (minors):\n\n* Unable to read\u002Funderstand English\n* Current manic or psychotic episode\n* Development disability precluding comprehension of study procedures\n* No routine access to a mobile phone, assessed by EHR review and during phone screen\n* No eligible parent or legal guardian to provide informed consent\n\nYouth (adults):\n\n* Unable to read\u002Funderstand English\n* Current manic or psychotic episode\n* Development disability precluding comprehension of study procedures\n* No routine access to a mobile phone, assessed by EHR review and during phone screen","24 Years",{"count":188,"type":21},100,[24],"Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death amongst youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be used to increase engagement with effective interventions such as suicide safety planning. The BRITE suicide safety planning app was developed on evidence-based principles and has undergone rigorous formative development and effectiveness evaluations. However, to optimize its functionality, commercial viability, and scale its implementation, issues related to user engagement needed to be addressed. This 3 month Pragmatic Randomized Trial will evaluate the impact of the ViraSafe app-an enhanced version of the BRITE suicide safety planning app-on improving engagement with coping skills and safety planning among suicidal adolescents by comparing its intervention components to those of the original BRITE app.",[29,192,193],"Mental Health Disorder","Anhedonia",[195,196,197,198,199,200,201],"depression","depressive disorder","mood disorder","mental disorders","suicidal behavior","suicidal thoughts","suicidal ideation","2026-08-10",{"date":204,"type":35},"2026-08-12",{"date":206,"type":35},"2026-06-18",{"date":208,"type":21},"2027-12-31",{"name":210,"class":41},"Ksana Health",3,{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":17,"minAge":220,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":22,"phases":223,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":70},"100545382","phase-1-warrior-care-cannabis-behavioral-health-100545382","NCT06381180","Warrior CARE: Cannabis Behavioral Health","Wayne Warrior CAnnabis Research and Education: Cannabis and Behavioral Health","CBH","Inclusion Criteria:\n\n* a healthy veteran who has served in a branch of the US armed forces\n* report using cannabis within the past year\n* currently meet DSM-5 criteria for PTSD and a score of 25 or greater on the CAPS-5 (the anchor, or index, trauma does not have to be related to military service)\n* between the ages of 19-69 years old\n* not seeking treatment for Cannabis Use Disorder\n* stable (i.e., under the care of a physician or therapist and not experiencing acute symptoms) on psychotropic medications and\u002For psychotherapy before the study begins (participants can be in treatment for PTSD)\n* agree to adhere to study procedures\n\nExclusion Criteria:\n\n* pregnant, lactating, or heterosexually active women and not using medically approved birth control\n* current or past bipolar or psychotic disorder as determined using the SCID-5\n* at immediate high risk for suicide based on the C-SSRS\n* current SUD other than Nicotine Use Disorder and Alcohol Use Disorder (mild or moderate)\n* allergies and\u002For other contradictions for using cannabis\n* any clinically significant medical problems\n* systolic\u002Fdiastolic BP \\>140\u002F90 mmHg or systolic BP \\\u003C95 mmHg\n* elevated liver function tests\n* exhibit cognitive impairment (\\\u003C80 IQ)\n* enrolled in another clinical trial or have received any drug as part of a research study within 30 days of dosing\n* used a prescription medication (with the exception of birth control) within 14 days of study entry that in the opinion of the medically responsible investigator will interfere with the safety of the participant or the study results\n* unable to provide informed consent","19 Years","69 Years",{"count":114,"type":21},[224,225],"PHASE1","PHASE2","This study is a randomized, controlled clinical trial to examine the therapeutic potential of cannabinoids for treating veterans with PTSD and suicidal ideation.",[228,229,29,230,231],"Post Traumatic Stress Disorder","Cannabis Use","Veterans","Marijuana","2026-08-04",{"date":234,"type":35},"2026-08-07",{"date":236,"type":35},"2025-09-22",{"date":238,"type":21},"2030-12-31",{"name":240,"class":69},"Wayne State University",{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":22,"phases":250,"briefSummary":251,"conditions":252,"keywords":255,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":258,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":70},"100560036","brief-skills-for-safer-living-brief-sfsl-100560036","NCT06571916","Brief Skills for Safer Living (Brief-SfSL)","Investigating the Efficacy of a Novel Therapy for Suicide Risk in Adults: A Randomized Controlled Trial of an Intensive Single Session of \"Brief Skills for Safer Living\"","Inclusion Criteria:\n\n* Suicidal ideation in the past week\n* Access to a computer or phone with a camera\n* Access to internet\n* Access to an emergency contact and hospital within commuting distance\n* Not receiving other psychotherapy\u002Fcounselling services concurrently\n* Willing to have the session recorded to determine therapy fidelity\n* Any psychiatric diagnosis is allowed\n* Follow-up visits with a psychiatrist and\u002For family doctor where a psychotherapeutic modality (e.g., Dialectical Behavioural Therapy, psychodynamic therapy, etc.) is not being used are allowable\n\nExclusion Criteria:\n\n* Inability to undergo psychotherapy in English\n* Presence of cognitive impairment that would limit consent and understanding of Brief Skills for Safer Living or study procedures\n* Active psychosis that impairs capacity to consent, understand study procedures, or participate\n* Unwilling or unable to provide informed consent\n* Previously enrolled in the Brief-SfSL pilot study\n* Unwilling or unable to communicate verbally",{"count":249,"type":21},150,[24],"The goal of this project is to assess the efficacy of Brief-Skills for Safer Living (Brief-SfSL) in a randomized control trial. The investigators will be testing 150 participants Canada-wide, half of which will be randomized to receive Brief-SfSL (B-TAU) and the other half will be randomized to receive Brief-SfSL after a 3 month waitlist (WL-TAU). The main questions this study seeks to answer are:\n\n* Is B-TAU more efficacious than WL-TAU for reducing suicidal thoughts at 3 months?\n* Is B-TAU more efficacious than WL-TAU at 3 months for reducing depression severity, anxiety, and anhedonia?\n* Is B-TAU more efficacious than WL-TAU at 3 months for improving social connectedness, emotional regulation, functioning (work, life, social), executive control and social problem-solving?\n* Are adverse events equivalent between B-TAU and WL-TAU at 3 months?",[253,29,254],"Suicide Prevention","Suicide and Self-harm",[256,257],"suicide","psychotherapy",{"date":232,"type":35},{"date":260,"type":35},"2025-11-17",{"date":262,"type":21},"2028-12-31",{"name":177,"class":69},{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":17,"minAge":271,"maxAge":50,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":274,"briefSummary":275,"conditions":276,"keywords":277,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":70},"100542980","a-pilot-evaluation-of-a-digital-peer-support-intervention-for-suicidal-adolescents-100542980","NCT06349915","A Pilot Evaluation of a Digital Peer Support Intervention for Suicidal Adolescents","SWEEP","Inclusion Criteria:\n\n* past-month history of suicidal thoughts\n* past-month history of Major depressive disorder\n* possession of apple or android smartphone with data plan\n\nExclusion Criteria:\n\n* inability to read\u002Fwrite in English\n* Active mania\n* Active psychosis\n* Autism spectrum disorder","14 Years",{"count":273,"type":21},46,[24],"Suicide risk has increased among youth in underserved communities, where access to mental healthcare is limited. To address this need, the investigator team plans to evaluate the preliminary efficacy of a brief, low-cost, culturally responsive digital intervention for ethnically diverse youth at risk for suicide in The Bronx, New York. In collaboration with community stakeholders, suicide recovery narratives, featuring adolescents' experiences related to recovery from suicidal thoughts will be developed. A smartphone ecological momentary assessment (EMA) app will be used to evaluate whether a curriculum of these narratives provides anti-suicidal benefits to at-risk adolescents.",[29],[278,279,280],"digital intervention","community participation","ecological momentary assessment","2026-07-29",{"date":283,"type":35},"2026-07-30",{"date":285,"type":21},"2026-08",{"date":287,"type":21},"2028-02",{"name":289,"class":69},"Albert Einstein College of Medicine",{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":22,"phases":297,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":301,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":70},"100649480","development-of-a-digital-acceptance-and-commitment-therapy-intervention-for-suicide-prevention-in-adults-through-co-design-100649480","NCT07733596","Development of a Digital Acceptance and Commitment Therapy Intervention for Suicide Prevention in Adults Through Co-design","* Inclusion Criteria Lived experience participants\n\n  1. Aged 18 years or older;\n  2. Have experienced suicidal thoughts and\u002For behaviors;\n  3. Able to read and communicate in Chinese; Professionals\n\n  \u003C!-- -->\n\n  1. Aged 18 years or older;\n  2. Professionals with experience relevant to suicide prevention, Acceptance and Commitment Therapy (ACT), digital mental health, or related fields;\n* Exclusion Criteria\n\n  1. Unable to provide informed consent or participate in study activities;\n  2. Currently experiencing acute suicide risk requiring immediate intervention;\n  3. Severe cognitive impairment or active psychotic symptoms that would prevent participation.",{"count":5,"type":21},[24],"Suicide is a major public health concern and there is a need for accessible and scalable interventions to support individuals experiencing suicidal thoughts. The aim of this study is to develop a digital Acceptance and Commitment Therapy (ACT) intervention for suicide prevention in Chinese adults through co-design. The study will involve literature review, interviews, and co-design activities to identify user needs, preferences, and contextual factors, and to develop the intervention. Following intervention development, a pilot study will be conducted to evaluate the feasibility, usability, acceptability, and user engagement of the intervention. Findings from this study will inform further refinement of the intervention and future evaluation studies.",[29,300,253],"Co-design","NOT_YET_RECRUITING","2026-07-23",{"date":281,"type":35},{"date":305,"type":21},"2026-07-15",{"date":307,"type":21},"2026-12-30",{"name":309,"class":69},"The Hong Kong Polytechnic University",{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":78,"sex":17,"minAge":316,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":22,"phases":319,"briefSummary":320,"conditions":321,"keywords":4,"overallStatus":301,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":326,"completionDateStruct":327,"leadSponsor":328,"locationsCount":70},"100648489","hand-in-hand-we-rise-xie-shou-gong-jin-100648489","NCT07722455","Hand in Hand, We Rise (Xie Shou Gong Jin)","Inclusion Criteria:\n\n* Adolescent inclusion criteria include: (a) is a registered student at one of the participating schools, (b) be between the ages of 11-15, (c) fluent in reading Chinese during the consent process, (d) be willing to participate in the YSSC curriculum during their psychoeducation class.\n* Caregiver inclusion criteria include: (a) age 18 or above, (b) can read and speak Chinese, (c) be a primary caregiver of an adolescent enrolled in the participating schools, and (d) willing to discuss perceived needs related to adolescent suicide prevention.\n* Teacher inclusion criteria include: (a) age 18 or above, (b) can read and speak Chinese, (c) be a full-time teacher of the participating schools.\n\nExclusion Criteria:\n\n* Individuals will be excluded from the study if they are determined to have symptoms that would prevent them from giving meaningful consent or participate in study activities, such as significant cognitive impairment.","11 Years",{"count":318,"type":21},1680,[24],"This study aims to conduct a cluster randomized controlled trial to assess the feasibility of implementing the \"Hand in Hand, We Rise\" (Xie Shou Gong Jin) multi-stakeholder collaborative school-based suicide prevention program in rural public junior high schools. Six schools will be randomly assigned in a 1:1 ratio to either the intervention group or the control group; the intervention group will simultaneously implement the \"Youth Strengths \\& Skills Curriculum (YSSC)\" curriculum for students, \"Life Gatekeeper\" training for teachers, and mental health information dissemination for caregivers. The primary objectives are to evaluate recruitment, retention, adherence, implementation fidelity, acceptability, and safety within real-world school settings, and to preliminarily estimate changes in indicators such as suicidal ideation, depression, anxiety, loneliness, help-seeking attitudes, mental health stigma, self-esteem, school climate, and bullying. The findings will provide parameters and an implementation basis for a subsequent large-scale, multi-school cluster randomized controlled trial.",[29,322,323,253],"Suicide Awareness","Mental Health","2026-07-20",{"date":302,"type":35},{"date":285,"type":21},{"date":175,"type":21},{"name":329,"class":69},"Brown University",{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":78,"sex":17,"minAge":336,"maxAge":186,"enrollmentInfo":337,"targetDuration":4,"studyType":22,"phases":339,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":42},"100472876","neural-derived-plasma-exosomal-micrornas-as-promising-novel-biomarkers-for-suicidality-and-treatment-outcome-in-adolescents-100472876","NCT05437588","Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents","Inclusion Criteria:\n\nAll participants:\n\n1. Physically healthy\n2. willing and able to provide informed consent (if under 18 also parent or guardian consent)\n\nMDD participants:\n\n1. A definite diagnosis of DSM-5\n2. a Children's Depression Rating Scale-Revised (CDRS-R) score \\>=30. Suicidal ideation participants: Columbia Suicide Severity Rating Scale (C-SSRS) score \\>=4 rated over the last two weeks.\n\nSuicide attempt group:\n\n1\\. Participants will have had an attempt in the previous two weeks that is serious enough to require medical attention and shows evidence of at least a medium level of intent on the Suicide Intent Scale.\n\nNon-psychiatric controls:\n\n1\\. No history of any major mental illness (excluding specific phobia) or substance use disorder.\n\nExclusion Criteria:\n\n* Exclusion criteria:\n\n  1. Pregnancy or lactation\n  2. post-partum state (being within 2 months of delivery or miscarriage);\n  3. homicide risk as determined by clinical interview\n  4. any of the following DSM-V diagnoses or categories: a) a lifetime history of psychotic disorder; b) alcohol or drug use disorder (except nicotine\u002Fcaffeine) within the last month; the use of any hallucinogen (except cannabis), including phencyclidine in the last month; c) bipolar disorder; d) pervasive developmental disorder; e) cognitive disorder; f) DSM-5 paranoid, schizoid, or schizotypal personality disorders (PDs) (participants with other PDs will be allowed as long as MDD criteria are met); g) anorexia nervosa.\n  5. recent myocardial infarction or unstable angina, active neoplasm in the past 6 months, immunosuppressive or corticosteroid therapy within the last month, chemotherapy, and head injury or loss of consciousness in the past 6 months\n  6. use of hallucinogens (except for cannabis), methamphetamine, or cocaine in the last 2 weeks.","10 Years",{"count":338,"type":21},240,[24],"This study is dedicated to help identify biomarkers for depression and suicide. The purpose of the study is to better understand these links to improve medical and psychiatric care in the future. This research is also to test the effects of standard treatment of depression on improvement in depressive and suicidal behavior and on biomarkers (e.g. miRNA) for these disorders.",[136,342,56,343,344,345,346,347,29],"Suicidal Ideas","MDD","Depression","Depression, Teen","Depression and Suicide","Depression in Adolescence","2026-07-10",{"date":350,"type":35},"2026-07-13",{"date":352,"type":35},"2022-10-01",{"date":354,"type":21},"2027-06-30",{"name":356,"class":69},"University of Alabama at Birmingham",{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":22,"phases":367,"briefSummary":368,"conditions":369,"keywords":372,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":389},"100636169","phase-2-inhaled-dmt-for-major-depressive-disorder-100636169","NCT07562191","Inhaled DMT for Major Depressive Disorder","Randomized, Double-Blind, Placebo-Controlled Phase IIb Trial of Inhaled N,N-Dimethyltryptamine (DMT) for Major Depressive Disorder","DMT-MDD","Inclusion Criteria:\n\n* 18 years or older, capable of making decisions, and able to provide informed consent.\n* Major Depressive Disorder (MDD) according to DSM-5 criteria\n* Current depressive episode of moderate to severe intensity\n* Episode duration of at least two weeks\n* Baseline MADRS score ≥ 20\n* No treatment changes (including antidepressants) in the 4 weeks prior to the study\n* Abstain from psychedelics ≥14 days before dosing (D0)\n\nExclusion criteria:\n\n* Major cardiac, hepatic, or renal disease; unstable cardiovascular conditions\n* Uncontrolled hypertension, QTc prolongation, arrhythmias, or valvular disease COPD or asthma\n* Severe obesity, uncontrolled diabetes, coagulopathy, thyroid disease, or glaucoma\n* Neurological risk (e.g., aneurysm, ↑ICP, epilepsy\u002Fseizures, severe disorders)\n* MAO deficiency or history of serotonin syndrome\n* Pregnant, breastfeeding, positive test, or no effective contraception\n* Secondary depression\n* Cluster B personality disorders (incl. borderline with ≥2 suicidal behaviors in past 12 months) or poor therapeutic rapport\n* Psychotic disorders, MDD with psychotic features, or first-degree family history of psychosis\u002Fbipolar disorder\n* Mania\u002Fhypomania\n* OCD, dissociative disorders, active PTSD, or decompensated eating disorders\n* Moderate-severe use disorder (past 6 months; except nicotine\u002Fcaffeine)\n* Lifetime ketamine, PCP, psychedelics, or MDMA use disorder\n* Current use of MAO inhibitors, unless discontinued at least 14 days prior to dosing\n* Psychedelic trial participation in past 12 months\n* Cognitive impairment affecting valid assessment",{"count":366,"type":21},140,[225],"This Phase 2b, randomized, double-blind, active-controlled clinical trial will evaluate the efficacy and safety of inhaled N,N-dimethyltryptamine (DMT) in adults with Major Depressive Disorder (MDD).\n\nThe study will test whether inhaled DMT can rapidly reduce depressive symptoms and suicide risk compared with a low-dose active comparator. A total of 140 participants will be randomized 1:1 to receive either 15 mg followed 1 hour later by 60 mg of inhaled DMT, or 1 mg followed 1 hour later by 4 mg of inhaled DMT.\n\nParticipants who do not achieve remission at Day 7 will enter an open-label extension and receive a high-dose DMT session on Day 14 (±3 days). All participants will be followed for up to 12 months to evaluate the durability of response, safety, functioning, and quality of life.",[343,370,371,57,29],"Major Depressive Disorder (MDD)","Major Depression",[373,374,375,376,377,378,379,380],"DMT","major depressive disorder","N,N-dimethyltryptamine","psychedelic therapy","inhaled DMT","vaporized DMT","suicidality","non invasive","2026-07-09",{"date":350,"type":35},{"date":384,"type":21},"2026-08-01",{"date":386,"type":21},"2027-08-01",{"name":388,"class":69},"Universidade Federal do Rio Grande do Norte",5,{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":397,"enrollmentInfo":398,"targetDuration":4,"studyType":22,"phases":400,"briefSummary":401,"conditions":402,"keywords":408,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":414,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":70},"100555424","phase-2-investigation-of-the-antidepressant-effects-of-2r6r-hnk-an-enhancer-of-synaptic-glutamate-release-in-treatment-resistant-depression-100555424","NCT06511908","Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression","An Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Ability of participant to understand and willingness to sign a written informed consent document. To verify this, participants must score \\>= 80% on the consent quiz.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. 18 to 70 years of age.\n4. All participants must have undergone a screening assessment under protocol 01-M-0254.\n5. Participants must fulfill DSM-IV or DSM-5 criteria for MDD, single episode or recurrent without psychotic features, based on clinical assessment and confirmed by a structured diagnostic interview (SCID-P). Participants must be experiencing a current major depressive episode lasting at least two weeks.\n6. Participants must have an initial score of \\>= 20 on the MADRS and a YMRS score of \\\u003C12 within one week of study entry and upon entry into Phase II.\n7. Ability to take intravenous medication and be willing to adhere to the (2R,6R)-HNK regimen.\n8. Participants must have a current or past history of lack of response to at least one adequate antidepressant trial (may be from the same chemical class), with at least one in the current major depressive episode, operationally defined using the modified Antidepressant Treatment History Form (ATHF); non-response to an adequate trial of ECT or TMS would count as an adequate antidepressant trial.\n9. For individuals of reproductive potential: use of highly effective contraception starting at the time of enrollment and agreement to use such a method during study participation and for an additional four weeks after the end of Study Phase II.\n10. For males of reproductive potential: use of condoms or other methods from the time of enrollment to ensure effective contraception with partner, and for an additional 90 days after the end of Phase II.\n11. Agreement to adhere to Lifestyle Considerations throughout study duration.\n12. Medically healthy, or with stable, treated, chronic medical conditions (provided any medications are not excluded)\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Current use of disallowed concomitant medications or transcranial magnetic stimulation (TMS) two weeks prior to the start of Phase II.\n2. Treatment with a reversible monoamine oxidase inhibitor (MAOI) four weeks prior to the start of Phase II.\n3. Treatment with fluoxetine, aripiprazole, or brexpiprazole five weeks prior to the start of Phase II.\n4. Treatment with clozapine or electroconvulsive therapy (ECT) four weeks prior to the start of Phase II.\n5. Ongoing treatment with moderate or strong CYP3A4\u002F5 inhibitors or inducers\n6. Lifetime history of deep brain stimulation.\n7. Previous antidepressant non-response to ketamine or esketamine (full course).\n8. No structured psychotherapy will be permitted during the total duration of the study. Participants unable or unwilling to stop psychotherapy will be unable to participate in the study.\n9. Pregnancy or lactation.\n10. Current psychotic features or a diagnosis of schizophrenia or any other psychotic disorder as defined in the DSM-IV or DSM-5.\n11. Participants with a history of DSM-IV substance or alcohol abuse or dependence, or DSM-5 substance use disorder (except for caffeine, nicotine, or cannabis), or moderate to severe alcohol use disorder, within the preceding three months. In addition, participants who are currently using drugs (except for caffeine, nicotine, or cannabis) must not have used illicit substances or known drugs of abuse in the two weeks prior to screen and must have a negative drug urine test (except for prescribed benzodiazepines or stimulants) prior to starting Phase II. Cannabis use is exclusionary if the use is daily, or if participants are unable to abstain during the study, or if function of daily life is impaired by use as determined by a clinician. Due to the interactions between cannabis and SSRIs, frequent cannabis use during previous antidepressant treatment will result in that treatment being considered a failed trial for eligibility purposes.\n12. Participants with a DSM-IV or DSM-5 Axis II diagnosis of borderline or antisocial personality disorder.\n13. Participants with a history of head injury that resulted in loss of consciousness exceeding five minutes (for the imaging component of the study).\n14. No serious, unstable medical illnesses including but not limited to the following body systems and organs or those that in the judgment of the Principal Investigator pose a risk to the participant's ability to safely participate in the study: Hepatic diseases (e.g. active viral hepatitis infection or cirrhosis of the liver, any liver disease with Child-Pugh score \\>=5), cardiovascular disease (including ischemic heart disease, coronary artery disease, congestive heart failure, poorly controlled hypertension due to risk of further blood pressure elevation and increase in demand on cardiac function from study drug), renal\u002Furologic (e.g chronic kidney disease or acute kidney injury, history of bladder dysfunction due to theoretical risk of ketamine-induced cystitis, moderate to severe renal impairment of any etiology), endocrinologic (including uncontrolled diabetes due to association with progressive abnormality of the microvasculature and nervous system), or neurologic disease (e.g. elevated intraocular pressure or history of or presence of diseases that are associated with elevated intracranial pressure).\n15. Participants with unstable clinical hyperthyroidism or hypothyroidism.\n16. Participants with one or more seizures without a clear and resolved etiology.\n17. Clinically significant abnormal laboratory tests specifically defined by:\n\n    * Alkaline phosphatase (Alk Phos) \\> 150 U\u002FL\n    * Alanine aminotransferase (ALT) \\> 55 U\u002FL\n    * Aspartate aminotransferase (AST) \\> 34 U\u002FL\n    * Total bilirubin (TB) \\> 1.2 mg\u002FdL\n    * Direct bilirubin (DB) \\> 0.5 mg\u002FdL\n    * 25-hydroxyvitamin D \\\u003C 20 ng\u002FmL\n    * Folate \\\u003C 2ng\u002FmL\n    * Vitamin B12 \\\u003C 200 pg\u002FmL\n18. Moderate to severe renal impairment with body surface area corrected eGFR \\\u003C60mL\u002Fmin.\n19. Participants who, in the Principal Investigator's judgment, pose a current serious suicidal or homicidal risk.\n20. Positive HIV test.\n21. Contraindications to MRS (metal in body, claustrophobia, etc. for imaging)\n22. Participants with COVID-19 or suspected COVID-19\n23. Inability to read and understand English. Non- English speakers will not be eligible as most of the required monitoring and rating instruments are not validated in languages other than English.","70 Years",{"count":399,"type":21},50,[225],"Background:\n\nMajor depressive disorder (MDD) is a serious mental illness that can put people at risk of self-harm and death. Many drugs are used to treat MDD, but it can take a long time for them to be effective. Researchers want to know if a faster-acting drug, (2R,6R)-hydroxynorketamine (HNK), can better treat the symptoms of MDD.\n\nObjective:\n\nTo test a study drug (HNK) in people with MDD.\n\nEligibility:\n\nPeople aged 18 to 70 years with MDD. They must have had a screening assessment under protocol 01-M-0254.\n\nDesign:\n\nParticipants will be tapered off their current MDD drugs over 2 to 5 weeks. They will stay off of the drugs for up to 2 weeks prior to starting the study medication and procedures. They will have a physical exam with blood tests. They will have tests of their heart function, mood, and thinking. They will answer questions about their symptoms. They may choose to have imaging scans and scans of their brain activity.\n\nHNK is given through a tube attached to a needle inserted into a vein. Participants will receive infusions on this schedule:\n\nThey will receive 4 infusions over 2 weeks. They will stay in the clinical center overnight after each infusion or for the duration of the study.\n\nThey will receive no drugs for 2 to 3 weeks.\n\nThey will have 4 more infusions over 2 weeks, with overnight stays after each or for the duration of the study.\n\nOne set of 4 infusions will be the HNK. The other set of 4 infusions will be a placebo. A placebo looks just like the real drug but contains no medicine. Participants will not know when they are getting the HNK or placebo.\n\n...",[29,403,132,131,130,129,123,404,405,344,406,407,118],"Depressive Disorder, Treatment-Resistant","Depressive Disorder, Major","Depressive Disorder","Mental Disorders","Mood Disorders",[136,132,141,409,410,411,139,412,413],"Neuropharmacology","Magnetic Resonance Imaging","Magnetoencephalography","Glutamate","Hydroxynorketamine",{"date":348,"type":35},{"date":416,"type":35},"2024-11-06",{"date":418,"type":21},"2027-07-01",{"name":150,"class":151},{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":17,"minAge":79,"maxAge":186,"enrollmentInfo":426,"targetDuration":4,"studyType":22,"phases":428,"briefSummary":429,"conditions":430,"keywords":432,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":446},"100527699","preventing-suicidal-behavior-with-diverse-high-risk-youth-in-acute-care-settings-100527699","NCT06151158","Preventing Suicidal Behavior With Diverse High-Risk Youth in Acute Care Settings","Inclusion Criteria:\n\n* Suicide Risk During Acute Care Visit (At least one item in risk assessment is required; check all that apply): \\_\\_\\_ Chief complaint of suicide-related concern (via Medical Record\u002FOther), \\_\\_\\_ Active suicidal ideation endorsed in past 1 month on validated suicide screener, \\_\\_\\_ Suicidal behavior in the past 3 months on validated suicide screener, \\_\\_\\_ Clinician indicated SI in past month or SA in past 3 months.\n* Have access to a cellular phone with the ability to receive phone calls and text messages over the 12-month follow- up period\n* Adolescent must be verbally fluent and can communicate, understand, and read in either English or Spanish\n* Adolescent has been\u002Fwill be discharged from a higher level of care (i.e. inpatient, day hospital, partial hospitalization program (PHP), or residential treatment program) and back in the community within 4 weeks of their acute care visit. \\[Note: this criterion does not apply to all patients - select N\u002FA if this is the case.\n\nExclusion Criteria:\n\n* Significant cognitive or developmental delays that prevent understanding or using SPI+ or IPT-A-SCI (includes inability to communicate verbally)\n* Altered mental status (acute psychosis, intoxication, or mania)\n* Unable or unwilling to provide informed consent (adults), assent (minors), or permission (parents\u002Fcaregivers)\n* The services offered through the study are not in the best clinical interest of the patient (e.g., presenting problem requires a different level of care or treatment approach).",{"count":427,"type":21},484,[24],"The study will compare the effectiveness of two relatively brief and scalable evidence-based interventions: the Stanley Brown Safety Planning Intervention and Follow-up Contacts (SPI+), a suicide-specific intervention that helps people prevent suicidal crises from escalating, and Interpersonal Psychotherapy for Adolescents Ultra Short Crisis Intervention (IPT-A SCI), a psychotherapeutic crisis intervention treatment for suicidal adolescents that teaches youth skills to prevent suicidal crises and addresses interpersonal problems that lead to suicidal crises. The results will inform the future standard of care for youth at risk for suicide presenting in the ED setting. This project focuses on suicidal youth ages 12-24 in five ethnically and racially diverse urban areas: Philadelphia, Pennsylvania; Baltimore, Maryland; Chapel Hill, North Carolina; St. Petersburg, Florida; and Northern Manhattan\u002Flower Bronx\u002Feastern Queens communities in New York City, New York.",[56,431,29,253],"Suicide Ideation",[433,434,435,436,253],"Safety Planning Intervention","Ultra-Brief Crisis","Interpersonal Psychotherapy for Adolescents","Emergency Department","2026-07-07",{"date":439,"type":35},"2026-07-08",{"date":441,"type":35},"2025-03-10",{"date":443,"type":21},"2029-08-15",{"name":445,"class":69},"Johns Hopkins University",6,{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":453,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":455,"targetDuration":4,"studyType":22,"phases":457,"briefSummary":458,"conditions":459,"keywords":461,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":70},"100543272","caring-connections-youth-suicide-detection-and-intervention-study-100543272","NCT06353711","Caring Connections Youth Suicide Detection and Intervention Study","CA-LINC Randomized Control Trial Study","CA-LINC","Inclusion Criteria:\n\nYouth:\n\n* 13 - 19 years old\n* Current or recent history (\\\u003C90 days) of suicide ideation, planning, or attempts or nonsuicidal self-injurious behaviors per youth or caregiver self-report or positive screen on the Patient Health Questionnaire Adolescent (PHQ-A), C-SSRS, or Ask Suicide-Screening Questions (ASQ).\n* Able to fluently speak and read English\n* Youth with a prior history of difficulty accessing services.\n* Written assent to participate in the study (\\\u003C18 years old)\n* Written consent from a parent\u002Flegal guardian\u002Fcaregiver to participate in the study (\\\u003C18 years old)\n* Written consent if the youth is ages 18-19\n\nParents\u002FLegal Guardians\u002FCaregivers:\n\n* The primary caregiver of a youth who meets the above inclusion criteria for the study\n* Over the age of 18\n* Able to fluently speak and read English\n* Without intellectual disabilities\n* Provide written consent to participate\n\nMental Healthcare and\u002For Healthcare Providers and\u002For Community Stakeholders:\n\n* Mental Health, behavioral health, substance use and\u002For health-related professionals who screen\u002Fassess for mental health and\u002For suicide risk or provide referrals, treatment, or follow-up care to youth with a prior history of difficulty accessing services in the surrounding treatment areas based on this risk or community stakeholder (i.e., faith-based leaders, agency directors, advocates, school administrators, hospital\u002Fcrisis directors, topical experts, etc.).\n* Over the age of 18\n* Able to fluently speak and read English\n* Without intellectual disabilities\n* Provide written consent to participate\n\nCare Coordinators:\n\n* Care coordinators who screen\u002Fassess for mental health and\u002For suicide risk or provide referrals, treatment, or follow-up care to underserved youth in the surrounding treatment areas.\n* Over the age of 18\n* Able to fluently speak and read English\n* Without intellectual disabilities\n\nExclusion Criteria:\n\nYouth:\n\n* Youth at imminent suicide risk (reported verbally and\u002For indicated on C-SSRS)\n* Youth who exhibit severe cognitive, language, or developmental delays\n* Youth not meeting inclusion criteria\n\nParents\u002FLegal Guardians\u002FCaregivers:\n\n* Not meeting the inclusion criteria listed above.\n\nMental Healthcare and\u002For Healthcare Providers and\u002For Community Stakeholders:\n\n* Not meeting the inclusion criteria listed above.",{"count":456,"type":21},180,[24],"The goal of this pilot randomized control trial (RCT) is to test the feasibility of Caring Connections, a Culturally Adapted Linking Individuals Needing Care (CA-LINC) suicide prevention care coordination intervention for high-risk suicidal youth. This consumer-, community-, and theory-driven care coordination intervention is designed to reduce suicide ideation and behavior (SIB) by improving service engagement. Connections is a 90-day intervention that integrates engagement and follow-up strategies to assess\u002Fmonitor suicide risk, facilitate service use referrals\u002Flinkages, develop\u002Frefine safety plans, and create villages of care. The intervention incorporates cultural promotive factors, empowerment, and motivational strategies aimed at supporting youth, enhancing strengths, promoting hope, improving family relationships, and reinforcing caring messages. Primary research questions include:\n\nIs Caring Connections feasible to use for suicidal high-risk youth? Does Caring Connections have the potential to reduce suicide ideation and behaviors among high-risk suicidal youth?\n\nFor the pilot RCT, 80 youth participants ages 13-19 who meet the inclusion criteria will be randomly assigned to one of two conditions: Caring Connections (n=40) or Treatment as Usual (n=40). Additionally, investigators will enroll 80 caregivers of youth meeting inclusion criteria and 20 Mental Healthcare, Healthcare Providers, Community Stakeholders, and\u002For Care Coordinators with experience working with suicidal youth. Researchers will compare those receiving Caring Connections with treatment as usual to see if suicidal ideation and behaviors, and engagement.",[29,253,431,460],"Suicide Attempt",[462,256,463,464],"Black youth","ideation","attempts","2026-07-06",{"date":437,"type":35},{"date":468,"type":35},"2025-08-14",{"date":470,"type":21},"2027-05-31",{"name":472,"class":69},"University of North Carolina, Chapel Hill",{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":481,"enrollmentInfo":482,"targetDuration":4,"studyType":22,"phases":484,"briefSummary":485,"conditions":486,"keywords":489,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":494,"completionDateStruct":495,"leadSponsor":497,"locationsCount":70},"100619545","sleep-and-circadian-interventions-for-college-students-at-high-risk-of-suicide-100619545","NCT07346014","Sleep and Circadian Interventions for College Students at High Risk of Suicide","Triple Chronotherapy + Transdiagnostic Sleep and Circadian Intervention (TSC+) for Suicidal Young Adults","REST-UP","Inclusion Criteria:\n\n* Enrolled or planning to enroll in treatment at COSTAR Intensive Outpatient Program\n* English language fluency and literacy sufficient to engage in study protocol\n* Suicidal ideation or suicide attempt in past month\n* Clinically significant sleep disturbance, operationalized as Pittsburgh Sleep Quality Index global PSQI score \\>= 7, and\u002For delayed bedtimes (\\>midnight), and\u002For \\>2 hours in sleep timing variability\n\nExclusion Criteria:\n\n* Non-affective psychosis per electronic health record (EHR) review and\u002For baseline clinical assessment, or symptom severity or psychosocial functioning impairments that preclude participation\n* Contraindications for either sleep deprivation or bright light therapy (e.g., bipolar disorder; seizure disorder; photosensitizing medication)\n* Intellectual disability precluding comprehension of study procedures\n* Evidence of untreated obstructive sleep apnea and\u002For restless legs syndrome\n* Life-threatening medical condition requiring immediate treatment (such as cancer; end stage disease)\n* Pregnancy","25 Years",{"count":483,"type":21},90,[24],"The purpose of this study is to examine the extent to which delivering sleep and circadian focused interventions in addition to evidenced based psychiatric care for depression and suicide risk may contribute to decreasing suicide risk among high risk young adults. Investigators will evaluate three interventions targeting sleep in acutely suicidal college students enrolled in intensive outpatient treatment. Participants will be randomly assigned to one of three intervention groups:\n\n1. Triple Chronotherapy (TCT)+ Transdiagnostic Sleep and Circadian Intervention (TSC)\n2. Transdiagnostic Sleep and Circadian Intervention (TSC)\n3. Sleep Feedback (SF) Participants will be followed for 6 months with primary outcome domains of suicidal thoughts and behaviors and depression evaluated by blinded clinicians at short (Days 1-4 of intervention), medium (2 months) and long (6 month) term intervals.",[487,488,344,29],"Sleep Disturbance","Sleep",[490,256,491],"sleep disturbance","triple chronotherapy","2026-07-02",{"date":437,"type":35},{"date":206,"type":35},{"date":496,"type":21},"2029-03",{"name":498,"class":69},"University of Pittsburgh",{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":17,"minAge":336,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":22,"phases":508,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":70},"100480895","scaling-up-e-connect-in-juvenile-probation-settings-100480895","NCT05541926","Scaling up e-Connect in Juvenile Probation Settings","Scaling up eConnect in Juvenile Probation Settings: a Hybrid Implementation Effectiveness Trial of a Digital Suicide Risk\u002FBehavior Identification and linkage-to Treatment System","Sample: County Probation Staff\n\nInclusion Criteria:\n\n* All probation agency leadership and officers employed by the partnering sites who are (a) at least 18 years of age and (b) conversant in English in participating study counties are eligible\n\nExclusion Criteria:\n\n* There are no exclusionary criteria and no special classes of participants.\n\nSample: County Treatment Staff\n\nInclusion Criteria:\n\n* All treatment staff (agency directors, supervisors and clinical line staff) employed by participating treatment agencies who are at least 18 years of age and conversant in English in participating study counties will be asked to participate\n\nExclusion Criteria:\n\n* There are no exclusionary criteria and no special classes of participants.\n\nSample: Local Facilitators\n\nInclusion Criteria:\n\n* All county\u002Flocal Justice Diversion Alternatives Initiative (JDAI) representatives that work with partnering sites who (a) are at least 18 years of age and (b) conversant in English in participating study counties are eligible\n\nExclusion Criteria:\n\n* There are no exclusionary criteria and no special classes of participants.\n\nSample: Probation Youth\n\nInclusion Criteria:\n\n* All youth who are on probation who are (a) 10-18 years of age and (b) conversant in English in participating study counties are eligible;\n\nExclusion Criteria:\n\n* There are no exclusionary criteria and no special classes of participants.",{"count":507,"type":21},3629,[24],"We propose to conduct research on strategies that support the successful scale-up of an evidence-based, suicidal risk and behavior identification and cross-system linkage programs for justice-involved youth (e-Connect), and to rigorously evaluate the implementation activities and associated costs that support that scale-up of e-Connect within 9 Indiana counties. Guided by the GPM and EPIS frameworks, this 4-year study will comprise 3 project phases: (1) Scale-Up Strategy Efforts, focused on preparing for scale-up; (2) e-Connect-scaleup implementation (2a Exploration and Preparation and 2b Implementation and Sustainment); and (3) Scale-Up Effectiveness Trial\u002FOutcome Evaluation. The current project draws on lessons learned from the e-Connect efficacy trial in NYS and research team leadership will serve as External Facilitators to support 9 Local Facilitators to ensure the successful transfer of knowledge, skill and expertise in delivering e-Connect in a new JJ system and geographic context, utilizing implementation strategies to support the more widespread, sustained and rigorous adoption of e-Connect. The study will include a learning community created by External Facilitators for Local Facilitators to provide support, to exchange strategies to handle implementation issues, to develop competencies in facilitation, and to guide implementation throughout the program. The learning community will help Local Facilitators navigate through the implementation stages of the study.",[29],"2026-06-28",{"date":513,"type":35},"2026-06-30",{"date":515,"type":35},"2023-05-02",{"date":517,"type":21},"2028-08-31",{"name":519,"class":69},"New York State Psychiatric Institute",{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":4,"eligibilityCriteria":526,"healthyVolunteers":12,"sex":17,"minAge":79,"maxAge":186,"enrollmentInfo":527,"targetDuration":4,"studyType":22,"phases":529,"briefSummary":530,"conditions":531,"keywords":4,"overallStatus":301,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":70},"100645259","peer-delivered-youth-suicide-prevention-in-nepal-100645259","NCT07680179","Peer Delivered Youth Suicide Prevention in Nepal","Innovations for Peer-delivered and Family-engaged Brief Interventions for Youth Suicide in Nepal: A Pilot Hybrid Type 2 Implementation Study","Inclusion Criteria:\n\nPeer Volunteers\n\n* Age ≥18 years\n* No current untreated mental disorder or suicide risk, as assessed and confirmed by a Nepali mental health specialist (MD or PhD)\n* Meets hiring and eligibility criteria of the local implementing partner NGO\n* Fluent in spoken Nepali\n\nTrial Youth Patient Participants\n\n* Age 12-24 years\n* Resident of the study site\n* Screens positive to the Nepali Ask Suicide Screening Questions or a lifetime history of a suicide attempt\n* Ability to provide informed consent or assent\n* For participants under 18 years of age, written informed consent from a legal guardian\n* Fluent in Nepali\n\nFamily Members (intervention group only)\n\n* Family member (defined as any individual that is a parent, grandparent, aunt\u002Funcle, or cousin as well as significant others) selected by the youth participants enrolled in the study\n* Resident of the study site\n* Over 18 years of age\n* Ability to provide informed consent or assent\n* Fluent in Nepali\n\nExclusion Criteria:\n\nPeer Volunteers\n\n* Plans to leave the peer volunteer role within the next 6 months\n* Unable to provide voluntary informed consent for any reason\n\nTrial Youth Patient Participants\n\n* Requires immediate psychiatric hospitalization at the time of assessment\n* Unable to provide informed consent or assent due to impaired decision-making capacity\n* Participants under 18 years of age without written informed consent from a legal guardian\n* Planning to leave the study area in the next 6 months\n\nFamily Members\n\n* Requires immediate psychiatric hospitalization at the time of assessment\n* Unable to provide informed consent or assent due to impaired decision-making capacity\n* Planning to leave the study area in the next 6 months",{"count":528,"type":21},160,[24],"South Asia has the highest suicide rate in the world with important risk profile differences from high-income settings. Investigators will conduct formative research to co-design a package of brief interventions and implementation strategies to prevent youth-suicide and then test the package in a pilot feasibility hybrid type 2 cluster randomized controlled trial in Nepal. Potential health impacts may be substantial as results can be applied not only in similar South Asian primary healthcare contexts, but also in low-resource settings in the US and abroad, where the suicide burden remains high.\n\nUsing experience-based co-design and equity-focused implementation frameworks, this study will assess the feasibility and acceptability of a Youth-focused, Peer-delivered, Family-engaged Suicide Prevention Package (YPF-SuPP) integrated within existing mhGAP services in Nepal's decentralized primary healthcare system. This pilot trial will generate preliminary data to inform the design of a future fully powered effectiveness trial and potential scale-up of youth suicide prevention strategies.",[29,253],"2026-06-25",{"date":492,"type":35},{"date":535,"type":21},"2026-06",{"date":537,"type":21},"2028-06",{"name":539,"class":69},"Yale University",{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":78,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":22,"phases":548,"briefSummary":549,"conditions":550,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":70},"100490823","effectiveness-and-implementation-of-a-clinician-decision-support-system-to-prevent-suicidal-behaviors-100490823","NCT05671133","Effectiveness and Implementation of a Clinician Decision Support System to Prevent Suicidal Behaviors","Inclusion Criteria:\n\n* Adult status (≥18 years-old);\n* Willing to provide an email address;\n* Presentation at the APS\n\nExclusion Criteria:\n\n* Inability to understand the study procedures and provide informed consent such as those with gross cognitive impairment (including florid psychosis), intellectual disability, dementia, acute intoxication, or the presence of extremely agitated or violent behavior\n* Decisions about inclusion\u002Fexclusion criteria will be made by the emergency department providers on duty at the time. These broad inclusion criteria maximize the clinical applicability of obtained results while the exclusion criteria ensure the ethical principle of respect for persons.",{"count":547,"type":21},4000,[24],"The primary aim of this project are to evaluate a comprehensive, practice-ready, and deployment-focused strategy for improving the prediction and prevention of suicide attempts among a sample of 4,000 patients presenting to an ED with a psychiatric concern. The first aim is to evaluate the effects of providing information about risk of patient suicidal behavior to ED clinicians. The investigators hypothesize that patients randomly assigned to have their clinician receive their risk score will have a lower rate of suicide attempts during 6-month follow-up and that this effect will be mediated by changes in clinician decision-making.",[29,56],"2026-06-16",{"date":553,"type":35},"2026-06-22",{"date":555,"type":35},"2025-02-25",{"date":557,"type":21},"2028-09-28",{"name":68,"class":69},{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":4,"eligibilityCriteria":565,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":566,"targetDuration":4,"studyType":22,"phases":568,"briefSummary":569,"conditions":570,"keywords":571,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":70},"100624065","evaluation-of-a-telehealth-case-management-intervention-to-prevent-suicide-among-soldiers-discharged-from-psychiatric-hospitalization-100624065","NCT07404787","Evaluation of a Telehealth Case Management Intervention to Prevent Suicide Among Soldiers Discharged From Psychiatric Hospitalization","SAFEGUARD Phase 2 Pathfinding Study","Inclusion Criteria:\n\n* Active duty Regular Army soldiers recently discharged from inpatient psychiatric care at a military treatment facility in the US\n* Access to telephone and computer (including smartphone)\n\nExclusion Criteria:\n\n* Impaired ability to provide informed consent\n* Terminal illness\n* Failure to complete baseline survey within 30 days of discharge\n* Positive screen for post-discharge suicide-related behaviors",{"count":567,"type":21},1500,[24],"This study evaluates the effectiveness of Pathfinding, a 6-month, remotely-delivered case management intervention designed to decrease suicidal behavior among active-duty Regular Army soldiers recently discharged from inpatient psychiatric treatment. Soldiers discharged from military treatment facilities across the U.S. will be identified and recruited to participate. Those who consent will be randomly assigned to receive either Treatment As Usual (TAU), which is the Army's standard post-discharge care, or TAU plus Pathfinding. Participants will complete a baseline assessment and follow-up assessments 6 months and 12 months later. The 6- and 12-month follow-up periods will also include examination of participants' electronic healthcare data and Army administrative data. The overall goals of the study are: (1) to evaluate whether Pathfinding decreases suicidal behaviors among soldiers transitioning from psychiatric hospitalization back to the community; and (2) to determine which discharged soldiers are most likely to benefit from the Pathfinding intervention versus TAU alone.",[29,460],[256,572,573,574,575,576],"suicide attempt","hospital discharge","military","intervention","case management","2026-06-08",{"date":579,"type":35},"2026-06-11",{"date":581,"type":35},"2026-02-24",{"date":583,"type":21},"2029-08-31",{"name":585,"class":586},"Uniformed Services University of the Health Sciences","FED",{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":220,"enrollmentInfo":594,"targetDuration":4,"studyType":22,"phases":596,"briefSummary":597,"conditions":598,"keywords":600,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":608,"locationsCount":610},"100575270","suicide-assessment-and-feasible-evidence-based-treatments-for-youth-living-with-hiv-in-lilongwe-100575270","NCT06770101","Suicide Assessment and Feasible Evidence-based Treatments for Youth Living With HIV in Lilongwe","Suicide Assessment and Feasible Evidence-based Treatments for Youth Living With HIV in Lilongwe: SAFETY Planning Pilot Trial","Inclusion Criteria:\n\n* Age 13-19\n* Diagnosed with HIV\n* Report current or historical suicidal ideation and behaviors (SIBs) on question 9 of the Patient Health Questionnaire modified for adolescents (PHQ-9-A) and the Ask Suicide-Screening questionnaire (ASQ)\n* Living in the clinic's catchment area with intention to remain for more than 1 year\n* Willing to provide consent (age 18+ or 16-17 years old and married and thereby considered emancipated minors per Malawi law) or assent with parental consent (age 13-17).\n\nExclusion Criteria:\n\n* Refuse to participate\n* Refuse to be audio-taped for in-depth interviews",{"count":595,"type":21},60,[24],"The overall aim of this study is to determine the feasibility, fidelity, acceptability, and preliminary effectiveness of the Friendship Bench +Safety Planning intervention in reducing suicidal ideation and behaviors (SIBs) and improving HIV engagement amongst adolescents living with HIV (ALWH) when compared to augmented usual care.",[599,29],"HIV",[599,29,57],"2026-06-04",{"date":603,"type":35},"2026-06-05",{"date":605,"type":35},"2025-07-01",{"date":607,"type":21},"2026-09",{"name":609,"class":69},"University of Pennsylvania",4,{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":4,"eligibilityCriteria":617,"healthyVolunteers":12,"sex":17,"minAge":79,"maxAge":50,"enrollmentInfo":618,"targetDuration":4,"studyType":22,"phases":619,"briefSummary":620,"conditions":621,"keywords":622,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":42},"100590134","transdiagnostic-sleep-and-circadian-intervention--bright-light-in-adolescents-with-elevated-depression-trans-cbl-100590134","NCT06963463","Transdiagnostic Sleep and Circadian Intervention + Bright Light in Adolescents With Elevated Depression (TranS-C+BL)","Transdiagnostic Sleep and Circadian Intervention + Bright Light in Adolescents With Elevated Depression","Inclusion Criteria:\n\n* Adolescents (12-18)\n* Current moderate to severe depression as measured by the PHQ-9M with a total score of greater than or equal to 11\n* Current clinically significant sleep disturbance measured by the PHQ-9-M sleep item greater than or equal to 2.\n* English language fluency and literacy sufficient to engage in study protocol.\n\nExclusion Criteria:\n\n* Evidence of obstructive sleep apnea,\n* Evidence of restless legs syndrome\n* Evidence of psychosis\n* Evidence of bipolar disorder\n* Evidence of a developmental disability precluding comprehension of study procedures per electronic health record and eligibility screening.",{"count":483,"type":21},[24],"The goal of this clinical trial is to adapt a sleep intervention for individuals representative of all demographic groups, including those who are at the highest risk for suicidal behavior. Sleep difficulties are a promising target for youth with suicidal thoughts and behavior to focus on as a prevention measure. We aim to increase intervention acceptability and impact by adapting it for the adolescent populations at highest risk for suicidal thoughts and behavior. The research project will compare Transdiagnostic Sleep and Circadian Intervention (TranS-C), an evidence based, modularized intervention that targets a range of sleep difficulties to a treatment as usual or control condition including providing weekly sleep feedback reports from data entered into a daily sleep diary and from wearing a sleep sensing, actigraphy watch. Participants in both conditions (TranS-C vs. Sleep Feedback) will wear an actigraphy sleep watch that monitors sleep, and complete daily sleep diaries via smartphone or email. Participants in the TranS-C condition will also wear bright light (BL) and blue blocking glasses each day as well as attend weekly or biweekly sessions with a Sleep Therapist. The sleep therapist will review sleep feedback during sessions.",[487,488,344,29],[623,624,625,626],"Sleep Disturbances","Objective Sleep","Subjective Sleep Difficulties","Minority Youth","2026-06-02",{"date":601,"type":35},{"date":630,"type":35},"2025-05-06",{"date":632,"type":21},"2027-07-31",{"name":498,"class":69},{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":639,"acronym":4,"eligibilityCriteria":640,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":641,"enrollmentInfo":642,"targetDuration":4,"studyType":22,"phases":644,"briefSummary":645,"conditions":646,"keywords":647,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":650,"lastUpdatePostDateStruct":651,"startDateStruct":653,"completionDateStruct":655,"leadSponsor":657,"locationsCount":70},"100622445","nudging-parental-actions-for-youth-suicide-prevention-100622445","NCT07383714","Nudging Parental Actions for Youth Suicide Prevention","Nudging Parental Action With A Randomized Controlled Trial of Text Messaging Intervention for Suicide Prevention","Inclusion Criteria:\n\n* Guardian must be able and willing to provide informed consent, and the participant must be able and willing to provide assent.\n* Parent and adolescent willingness and ability to participate in study procedures and complete assessments at baseline, 6 weeks, and 12 weeks.\n* Presentation to the ED for a suicide-related emergency, defined as suicidal ideation within the last 2 weeks or a suicide attempt within the past month.\n* Adolescents aged 12-17 years during the consent.\n* Access to a mobile phone with text messaging capability for the parent\u002Flegal guardian.\n* Ability to communicate in English.\n\nExclusion Criteria:\n\n* Absence of a legal guardian capable of providing consent.\n* Parents\u002Flegal guardians without access to a mobile phone with texting capability.\n* Inability to communicate in English.\n* Adolescents in state custody or under legal restrictions that prevent study participation.\n* Adolescents involved in the justice system in a manner that would interfere with study participation.\n* Adolescents with autism spectrum disorder or intellectual development disorder needing substantial or very substantial support","17 Years",{"count":643,"type":21},129,[24],"The goal of the study is to determine effectiveness of a behaviorally informed text messaging intervention to help parents increase safety practices and reduce their teens' access to lethal means following a suicide-related emergency department visit.",[29,460],[256,648,649],"digital health","lethal means restriction","2026-06-01",{"date":652,"type":35},"2026-06-03",{"date":654,"type":21},"2026-06-15",{"date":656,"type":21},"2027-08-31",{"name":658,"class":69},"University of Texas Southwestern Medical Center",{"id":660,"slug":661,"hasResults":12,"nctId":662,"briefTitle":663,"officialTitle":664,"acronym":665,"eligibilityCriteria":666,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":667,"targetDuration":4,"studyType":22,"phases":668,"briefSummary":670,"conditions":671,"keywords":672,"overallStatus":301,"whyStopped":4,"lastUpdateSubmitDate":677,"lastUpdatePostDateStruct":678,"startDateStruct":680,"completionDateStruct":681,"leadSponsor":683,"locationsCount":4},"100628410","phase-4-self-hanging-patient-and-hyperbaric-oxygen-therapy--siphon-study-100628410","NCT07461272","Self-hangIng Patient and Hyperbaric Oxygen Therapy _ SIPHON Study","Self-hangIng Patient and Hyperbaric Oxygen Therapy - SIPHON Study \u002F Place de l'Oxygénothérapie Hyperbare Dans la Prise en Charge Des Tentatives de Pendaison","SIPHON","Inclusion Criteria:\n\nPatients who present, following an attempted hanging, neurological distress defined by the presence of one or more of the following criteria:\n\n* Glasgow score \\\u003C 13\u002F15\n* Confusional syndrome\n* Psychomotor agitation Who most of the time require optimal neuroprotection by sedation and invasive mechanical ventilation for the purpose of protecting the airways.\n* Patient aged over 18 years,\n* Suicide attempt by hanging without cardiocirculatory arrest,\n* Patient insured socially and able to understand the information provided\n\nExclusion Criteria:\n\n* Response time exceeded by \\> 6 hours from the hanging\n* Attempted hanging with immediate return to normal consciousness\n* Refusal of consent from the family or trusted person at the time of inclusion in the study,\n* Patients and\u002For families unable to understand the information provided",{"count":399,"type":21},[669],"PHASE4","During an attempted hanging, patients present severe neurological distress that can lead to major neuropsychiatric sequelae. These sequelae are notably due to significant cerebral edema related to hanging. Hyperbaric Oxygen therapy is known to reduce cerebral edema and improve cerebral perfusion. The main objective of the study is to evaluate in patients who have attempted hanging without presenting cardio-respiratory arrest, the effect of one Hyperbaric Oxygen therapy session in addition to standard intensive care management on a potential reduction in short-term neurological sequelae. Patients will benefit from either standard management or standard management associated with one Hyperbaric Oxygen therapy session",[29],[673,674,675,676],"Hanging","Neurological sequelae","Hyperbaric oxygen therapy","Intensive care","2026-05-20",{"date":679,"type":35},"2026-05-22",{"date":535,"type":21},{"date":682,"type":21},"2028-12",{"name":684,"class":69},"University Hospital, Lille"]